Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays an important clinical ICU role. The administration of iNO is usually performed through an endotracheal tube, but spontaneously breathing patients might also benefit from iNO administration. The use of the non-invasive administration of iNO through high-flow nasal cannula (HFNC) allows for NO delivery in spontaneously breathing patients who still need supplemental oxygen and positive airway pressure. A simple method to administer NO through HFNC is described here using standard commercially available NO administration and HFNC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10886258 | PMC |
| http://dx.doi.org/10.3390/arm92010012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oxidized high-density lipoprotein associates with cardiometabolic dysfunction in coronary artery disease and acute coronary syndrome.
J Intern Med
September 2025
Department of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
Background: High-density lipoprotein (HDL) function, rather than its concentration, plays a crucial role in the development of coronary artery disease (CAD). Diminished HDL antioxidant properties, indicated by elevated oxidized HDL (nHDL) and diminished paraoxonase-1 (PON-1) activity, may contribute to vascular dysfunction and inflammation. Data on these associations in CAD patients, including acute coronary syndrome (ACS), remain limited.
View Article and Find Full Text PDFUS-triggered on-demand NO-releasing biomimetic nanoparticle to Remodel endothelial microenvironment for enhancing atherosclerosis-specific gas therapy.
Mater Today Bio
October 2025
Department of Vascular Surgery, The Affiliated Hospital of Southwest Medical University, 646000, Luzhou, China.
Atherosclerosis (AS) is a chronic inflammatory disease driven by endothelial dysfunction, vascular smooth muscle cell proliferation, and insufficient resolution of inflammation. Nitric oxide (NO) plays a crucial role in vascular homeostasis by promoting endothelial cell proliferation, maintaining endothelial integrity, suppressing smooth muscle cell hyperplasia, and exerting potent anti-inflammatory effects. However, clinical application of NO is hindered by its short half-life, lack of targeting, and uncontrolled release.
View Article and Find Full Text PDFAcoustic therapy for allergic rhinitis and chronic rhinosinusitis: modulating microbiome, immunity and well-being.
Front Allergy
August 2025
Department of Surgery, University of Auckland, Auckland, New Zealand.
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are common respiratory conditions that significantly impact patient health and contribute to substantial healthcare burdens. While conventional treatments offer symptom relief, many patients continue to experience persistent symptoms, side effects, or resistance to standard therapies. This highlights the growing need for novel, non-invasive, and sustainable therapeutic strategies to manage chronic airway inflammation.
View Article and Find Full Text PDFVascular Endothelium in Health and Disease: Structure, Function, Assessment and Role in Metabolic Disorders.
Vasc Health Risk Manag
September 2025
Department of Functional Diagnostics and Physical Medicine, Pomeranian Medical University in Szczecin, Szczecin, 71-210, Poland.
The vascular endothelium is responsible for regulating vascular tone, maintaining fluid homeo-stasis, and preventing platelet aggregation, exhibits regulatory properties in vasorelaxation and vasoconstriction - it produces, among others, nitric oxide and endothelin. The imbalance of vasoactive molecules leads to the loss of their function, known as endothelial dysfunction. Impaired endothelial function is observed in people with metabolic disorders, often preceding the onset of the disease by several years.
View Article and Find Full Text PDFThe Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.
Rev Cardiovasc Med
August 2025
Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Heart failure with reduced ejection fraction (HFrEF) is a progressive condition that is associated with high rates of morbidity, frequent hospitalizations, and significant mortality. Despite advancements in guideline-directed medical therapy (GDMT), many patients continue to be at risk for worsening heart failure (WHF). Vericiguat is a novel soluble guanylate cyclase (sGC) stimulator that targets the impaired nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway.
View Article and Find Full Text PDF